Annual CFF
$69.00 K
-$538.00 K-88.63%
31 December 2023
Summary:
Adverum Biotechnologies annual cash flow from financing activities is currently $69.00 thousand, with the most recent change of -$538.00 thousand (-88.63%) on 31 December 2023. During the last 3 years, it has fallen by -$355.92 million (-99.98%). ADVM annual CFF is now -99.98% below its all-time high of $355.99 million, reached on 31 December 2020.ADVM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
+$116.00 K+100.00%
30 September 2024
Summary:
Adverum Biotechnologies quarterly cash flow from financing activities is currently $0.00, with the most recent change of +$116.00 thousand (+100.00%) on 30 September 2024. Over the past year, it has increased by +$105.00 thousand (+100.00%). ADVM quarterly CFF is now -100.00% below its all-time high of $204.25 million, reached on 30 September 2020.ADVM Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$119.93 M
+$105.00 K+0.09%
30 September 2024
Summary:
Adverum Biotechnologies TTM cash flow from financing activities is currently $119.93 million, with the most recent change of +$105.00 thousand (+0.09%) on 30 September 2024. Over the past year, it has increased by +$119.78 million (+82610.34%). ADVM TTM CFF is now -68.64% below its all-time high of $382.38 million, reached on 30 September 2020.ADVM TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADVM Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -88.6% | +100.0% | +10000.0% |
| 3 y3 years | -100.0% | 0.0% | +4901.3% |
| 5 y5 years | -99.9% | +100.0% | +8472.5% |
ADVM Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -100.0% | at low | -100.0% | +100.0% | -0.0% | >+9999.0% |
| 5 y | 5 years | -100.0% | at low | -100.0% | +100.0% | -68.6% | >+9999.0% |
| alltime | all time | -100.0% | at low | -100.0% | +100.0% | -68.6% | >+9999.0% |
Adverum Biotechnologies Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $119.93 M(+0.1%) |
| June 2024 | - | -$116.00 K(-100.1%) | $119.83 M(-0.1%) |
| Mar 2024 | - | $119.88 M(>+9900.0%) | $119.95 M(>+9900.0%) |
| Dec 2023 | $69.00 K(-88.6%) | $166.00 K(-258.1%) | $69.00 K(-52.4%) |
| Sept 2023 | - | -$105.00 K(-1412.5%) | $145.00 K(-42.0%) |
| June 2023 | - | $8000.00(>+9900.0%) | $250.00 K(-58.6%) |
| Mar 2023 | - | $0.00(-100.0%) | $604.00 K(-0.5%) |
| Dec 2022 | $607.00 K(-74.7%) | $242.00 K(>+9900.0%) | $607.00 K(-18.0%) |
| Sept 2022 | - | $0.00(-100.0%) | $740.00 K(0.0%) |
| June 2022 | - | $362.00 K(>+9900.0%) | $740.00 K(-17.3%) |
| Mar 2022 | - | $3000.00(-99.2%) | $895.00 K(-62.7%) |
| Dec 2021 | $2.40 M(-99.3%) | $375.00 K(>+9900.0%) | $2.40 M(-0.0%) |
| Sept 2021 | - | $0.00(-100.0%) | $2.40 M(-98.8%) |
| June 2021 | - | $517.00 K(-65.6%) | $206.65 M(-1.1%) |
| Mar 2021 | - | $1.50 M(+300.3%) | $208.87 M(-41.3%) |
| Dec 2020 | $355.99 M(+1162.8%) | $376.00 K(-99.8%) | $355.99 M(-6.9%) |
| Sept 2020 | - | $204.25 M(+7379.1%) | $382.38 M(+114.8%) |
| June 2020 | - | $2.73 M(-98.2%) | $178.03 M(+0.5%) |
| Mar 2020 | - | $148.62 M(+455.2%) | $177.19 M(+528.5%) |
| Dec 2019 | $28.19 M(-59.7%) | $26.77 M(<-9900.0%) | $28.19 M(+1915.1%) |
| Sept 2019 | - | -$91.00 K(-104.8%) | $1.40 M(-5.2%) |
| June 2019 | - | $1.88 M(-608.4%) | $1.48 M(-773.5%) |
| Mar 2019 | - | -$370.00 K(+1661.9%) | -$219.00 K(-100.3%) |
| Dec 2018 | $69.95 M | -$21.00 K(+40.0%) | $69.95 M(-19.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$15.00 K(-108.0%) | $86.61 M(+0.3%) |
| June 2018 | - | $187.00 K(-99.7%) | $86.39 M(+0.0%) |
| Mar 2018 | - | $69.80 M(+319.3%) | $86.36 M(+415.6%) |
| Dec 2017 | $16.75 M(+2912.2%) | $16.64 M(-7064.4%) | $16.75 M(+5373.2%) |
| Sept 2017 | - | -$239.00 K(-254.2%) | $306.00 K(-44.3%) |
| June 2017 | - | $155.00 K(-17.1%) | $549.00 K(+14.1%) |
| Mar 2017 | - | $187.00 K(-7.9%) | $481.00 K(-13.5%) |
| Dec 2016 | $556.00 K(-99.6%) | $203.00 K(+4975.0%) | $556.00 K(+612.8%) |
| Sept 2016 | - | $4000.00(-95.4%) | $78.00 K(-37.1%) |
| June 2016 | - | $87.00 K(-66.8%) | $124.00 K(-15.6%) |
| Mar 2016 | - | $262.00 K(-195.3%) | $147.00 K(-99.9%) |
| Dec 2015 | $138.86 M(-16.1%) | -$275.00 K(-650.0%) | $138.86 M(+0.2%) |
| Sept 2015 | - | $50.00 K(-54.5%) | $138.63 M(-46.0%) |
| June 2015 | - | $110.00 K(-99.9%) | $256.57 M(-15.4%) |
| Mar 2015 | - | $138.97 M(<-9900.0%) | $303.42 M(+83.4%) |
| Dec 2014 | $165.44 M(+6571.0%) | -$505.00 K(-100.4%) | $165.44 M(-0.9%) |
| Sept 2014 | - | $117.99 M(+151.3%) | $166.93 M(+236.3%) |
| June 2014 | - | $46.96 M(+4595.7%) | $49.64 M(+1460.9%) |
| Mar 2014 | - | $1.00 M(+2.0%) | $3.18 M(+28.2%) |
| Dec 2013 | $2.48 M(+396.0%) | $980.00 K(+40.0%) | $2.48 M(+65.3%) |
| Sept 2013 | - | $700.00 K(+40.0%) | $1.50 M(+87.5%) |
| June 2013 | - | $500.00 K(+66.7%) | $800.00 K(+166.7%) |
| Mar 2013 | - | $300.00 K | $300.00 K |
| Dec 2012 | $500.00 K | - | - |
FAQ
- What is Adverum Biotechnologies annual cash flow from financing activities?
- What is the all time high annual CFF for Adverum Biotechnologies?
- What is Adverum Biotechnologies annual CFF year-on-year change?
- What is Adverum Biotechnologies quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Adverum Biotechnologies?
- What is Adverum Biotechnologies quarterly CFF year-on-year change?
- What is Adverum Biotechnologies TTM cash flow from financing activities?
- What is the all time high TTM CFF for Adverum Biotechnologies?
- What is Adverum Biotechnologies TTM CFF year-on-year change?
What is Adverum Biotechnologies annual cash flow from financing activities?
The current annual CFF of ADVM is $69.00 K
What is the all time high annual CFF for Adverum Biotechnologies?
Adverum Biotechnologies all-time high annual cash flow from financing activities is $355.99 M
What is Adverum Biotechnologies annual CFF year-on-year change?
Over the past year, ADVM annual cash flow from financing activities has changed by -$538.00 K (-88.63%)
What is Adverum Biotechnologies quarterly cash flow from financing activities?
The current quarterly CFF of ADVM is $0.00
What is the all time high quarterly CFF for Adverum Biotechnologies?
Adverum Biotechnologies all-time high quarterly cash flow from financing activities is $204.25 M
What is Adverum Biotechnologies quarterly CFF year-on-year change?
Over the past year, ADVM quarterly cash flow from financing activities has changed by +$105.00 K (+100.00%)
What is Adverum Biotechnologies TTM cash flow from financing activities?
The current TTM CFF of ADVM is $119.93 M
What is the all time high TTM CFF for Adverum Biotechnologies?
Adverum Biotechnologies all-time high TTM cash flow from financing activities is $382.38 M
What is Adverum Biotechnologies TTM CFF year-on-year change?
Over the past year, ADVM TTM cash flow from financing activities has changed by +$119.78 M (+82610.34%)